?On-off? phenomenon in Parkinson's disease: Correlation to the concentration of dopa in plasma
- 1 September 1984
- journal article
- research article
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 59 (3) , 229-240
- https://doi.org/10.1007/bf01250010
Abstract
To investigate the relation between “on-off” fluctuations in symptomatology and bioavailability of dopa in patients with Parkinson's disease, five Parkinsonian patients with pronounced “on-off” symptoms were studied. Continuously during the study the degree of disability in the patients was registered. Every one hour, and in addition, whenever there was a change from “on” to “off” or vice versa, a blood sample was collected for dopa determination. Since dopa is transported from plasma into the brain by a saturable carrier for which it has to compete with endogenous large neutral amino acids (LNAA), the concentrations of these competitors were measured too. In four of the patients there were considerable oscillations in the plasma dopa concentration during the day; in one of these patients the highest value was as much as 12 times higher than the lowest value. These dramatic fluctuations in the absolute concentration of dopa in plasma had a major influence on the relative dopa concentrations (calculated as the ratio dopa/sum of LNAA) as the fluctuations in the concentrations of LNAA in plasma were much less pronounced. Consequently, the absolute and the relative concentrations of dopa in plasma were highly parallelled. In four of the five patients “on”-periods began within one hour after a peak in the concentration of dopa in plasma and in the fifth patient five out of seven “on”-periods were preceded by a rise in plasma dopa concentration within the same time interval. From the present data it could be concluded that the “on-off” phenomenon in Parkinson's disease, at least partly, is due to oscillations in the concentration of dopa in plasma. A reduction in the variations of the concentration of dopa in plasma seems to be necessary to overcome the “on-off” problem. The introduction of a slow release preparation of dopa is therefore urgently warranted. The concentration of LNAA in plasma must, however, also be considered in this context.Keywords
This publication has 20 references indexed in Scilit:
- Problems associated with long-term levodopa treatment of Parkinson's diseaseActa Neurologica Scandinavica, 1983
- ‘On—off’ effects: the new challenge in parkinsonismTrends in Neurosciences, 1983
- COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPAThe Lancet, 1982
- BRAIN TISSUE AND PLASMA ASSAY OF L‐DOPA AND α‐METHYLDOPA METABOLITES BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTIONJournal of Neurochemistry, 1979
- Factors Influencing the Occurrence of “on‐off” Symptoms during Long‐Term Treatment with L‐dopaActa Medica Scandinavica, 1978
- Variability of L-Dopa Absorption in ManAustralian and New Zealand Journal of Medicine, 1974
- VARIATION OF LEVODOPA METABOLISM WITH GASTROINTESTINAL-ABSORPTION SITEThe Lancet, 1974
- SUSTAINED-RELEASE LEVODOPAThe Lancet, 1973
- DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with parkinson's disease before and during treatment with L-dOPAClinica Chimica Acta; International Journal of Clinical Chemistry, 1973
- Plasma Concentration of Levodopa in Patients with Parkinson’s DiseaseEuropean Neurology, 1973